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Abstract
Gliomas account for more than 50% of all primary brain tumors. The worst prognosis is associated with gliomas of
astrocytic origin, whereas gliomas with an oligodendroglial origin offer higher sensitivity to chemotherapy, especially
when oligodendroglioma cells display 1p19q deletions. Temozolomide (TMZ) provides therapeutic benefits and is
commonly used with radiotherapy in highly malignant astrocytic tumors, including glioblastomas. The actual benefits
of TMZ during long-term treatment in oligodendroglioma patients have not yet been clearly defined. In this study,
we have investigated the effects of such a long-term TMZ treatment in the unique Hs683 oligodendroglioma model.
We have observed increased TMZ sensitivity of Hs683 orthotopic tumors that were previously treated in vitro with
months of progressive exposure to increasing TMZ concentrations before being xenografted into the brains of
immunocompromised mice. Whole-genome and proteomic analyses have revealed that this increased TMZ sensi-
tivity of Hs683 oligodendroglioma cells previously treated for long periods with TMZ can be explained, at least partly,
by a TMZ-induced p38-dependant dormancy state, which in turn resulted in changes in amino acid metabolism
balance, in growth delay, and in a decrease in Hs683 oligodendroglioma cell-invasive properties. Thus, long-term
TMZ treatment seems beneficial in this Hs683 oligodendroglioma model, which revealed itself unable to develop
resistance against TMZ.
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Introduction
Gliomas are themost common primary brainmalignancy found in adults
and include astrocytomas, oligodendrogliomas, and ependymomas
[1,2]. Current recommendations are that patients with high-grade
astrocytomas should undergo maximum surgical resection, followed
by concurrent radiation and chemotherapy with the alkylating drug
temozolomide (TMZ). Indeed, since the clinical trial published in
2005 by Stupp et al., concomitant and adjuvant chemoradiotherapy
with TMZ has become the standard treatment of high-grade gliomas
from astroglial origin [3,4]. This treatment is now also widely used to
treat oligodendrogliomas [5]. Moreover, patients whose oligodendro-
glioma displays 1p/19q chromosome deletions can be safely treated
with single-agent TMZ [6,7].
TMZ belongs to the triazene family of compounds, which are a
group of alkylating agents whose mechanism of antitumor effects is
mediated in part through DNA methylation of O(6)-guanine [8]. The
biologic end point of TMZ-induced antitumor effects in glioma cells
relates to apoptosis-related cell death [9,10]. TMZ also exerts marked
antiangiogenic effects in experimental gliomas [11,12].
Gliomas, including oligodendroglioma, can develop TMZ resistance,
which can be partly mediated by O(6)-methylguanine-DNA methyl-
transferase (MGMT), which demethylates TMZ-methylated guanosine
[13,14]. When treated with TMZ, glioma cells also defend themselves
through proautophagic mechanisms [15,16], which, if remain sus-
tained, lead to apoptosis [9,10]. Glioma cells become sensitized to
TMZ treatment, resulting in increased apoptosis, when Na+/H+ ex-
changer regulating factor 1 expression is reduced [17].
However, the cellular effects induced by long-term treatment (LTT)
of oligodendroglioma cells with TMZ remain unknown. The present
study aimed to characterize such long-term TMZ treatment under
in vitro and in vivo experimental conditions in the human Hs683 oli-
godendroglioma model. The validation of the oligodendroglial origin of
the Hs683 model has been performed in several steps: Hs683 tumor
cells are 1p19q codeleted [18] and are sensitive to proapoptotic chemo-
therapy [18] and to TMZ [11,19,20] under in vivo orthotopic brain
xenograft conditions. Moreover, Hs683 cells display high levels of ex-
pression of integrin β4 [21] as human biopsy oligodendrogliomas do
[21,22]. Hs683 cells do not express the human 1p-distal ATAD 3B
gene, which is highly expressed in astroglioma cells [23]. Finally, they
contain only oneNotch2 gene copy per diploid genome as seen in oligo-
dendrogliomas [24], in which loss of the 1p centromeric marker within
intron 12 of the Notch2 gene is associated with a favorable prognosis
in oligodendroglioma patients [25]. Lastly, we have shown that BEX2
(the brain-expressed X-linked gene) interferes with Hs683 oligodendro-
glioma cell biology in a manner that markedly differs from what is
observed in astrocytic tumors [26]. As illustrated in the Results sec-
tion (Figure 1), Hs683 orthotopic xenografts developing in the brains
of immunocompromised mice display highly invasive properties. Thus,
the Hs683 oligodendroglioma model might correspond to the few
glioblastomas displaying an oligodendroglial origin [27] and/or com-
ponent [28].
In the present study, Hs683 oligodendroglioma cells have been cul-
tured for months in incremental concentrations of TMZ until Hs683
cells were able to grow in culture medium containing 1 mM TMZ.
Before long-term adaptation, the native (preadaptation) TMZ-related
in vitro IC50 value (i.e., the concentration that decreases by 50% the
growth of glioma cells after 3 days of culture in presence of TMZ)
ranges between 100 and 300 μM [11,15,29]. Whole-genome analyses
have been performed in Hs683 cells left untreated (and thereafter
named TMZ-sensitive, i.e., TMZ-S Hs683 cells) and in long-term
TMZ-treated (TMZ-LTT) Hs683 cells. TMZ-S and TMZ-LTT
Hs683 cells have also been orthotopically grafted into the brain of
immunocompromised mice, and the effects of chronic TMZ treat-
ments have been analyzed.
Materials and Methods
Cell Cultures and Compounds
The human Hs683 oligodendroglioma (ATCC code HTB-138),
U373 (ATCC code HTB-17) and T98G (ATCC code CRL-1690) as-
troglioma, and HT-29 colon cancer (ATCC code HTB-38) cell lines
were obtained from the American Type Culture Collection (ATCC,
Manassas, VA) and maintained in our laboratory as detailed previously
[11,18–21].
In Vitro Long-term Treatment of Hs683 Oligodendroglioma
Cells with TMZ
Hs683 cells either have been left untreated (TMZ-S Hs683 cells)
or were cultured for months in incremental concentrations of TMZ
(TMZ-LTT Hs683 cells). Firstly, they were cultured with 100 nM
TMZ for 4 weeks, then with 1 μMTMZ for 5 weeks, then with 10 μM
TMZ for 12 weeks, then with 100 μMTMZ for 12 weeks, and finally
with 1 mM TMZ for 4 weeks. TMZ-LTT Hs683 cells were then cul-
tivated for 8 weeks without TMZ treatment (washout) before in vivo
orthotopic grafting and genomic analyses.We choose this 8-week period
of washout to investigate as whether TMZ-LTT Hs683 cells retained
differences in terms of biologic characteristics compared with Hs683
cells left untreated with TMZ. This means that the selection pressure
exerted by TMZ was partially undone.
In Vivo Orthotopic Grafting of Hs683 Oligodendroglioma
Cells into the Brains of immunocompromised Mice
TMZ-S and TMZ-LTT Hs683 tumor cells were grafted orthotopi-
cally into the brains of nude mice as described previously [18–21]. In
each experiment, all mice (8-week-old female nu/nu mice; 21-23 g;
Iffa Credo, Charles Rivers, Arbresle, France) had 100,000 Hs683 cells
implanted on the same day into the left temporal lobe. Mice were then
treated or not with TMZ (80 mg/kg per os) three times per week for
3 weeks starting at day 5 after graft. Each experimental group contained
11 mice. All the in vivo experiments described in the present study
were performed on the basis of Authorization No. LA1230509 of
the Animal Ethics Committee of the Federal Department of Health,
Nutritional Safety and the Environment (Belgium).
In Vitro Determination of Mitotic Rates
The number of mitotic cells in TMZ-S versus TMZ-LTT Hs683
cells was characterized in vitro. Cells were followed for 72 hours, and
mitotic cells were detected manually on pictures on the basis of their
characteristic roundness and brightness. The data were expressed as a
total number of mitotic cells counted at the 24th, 48th, and 72nd hours
after plating on a 1-mm2 area. For each condition, 12microscopic fields
of 1 mm2 each on three replicates have been analyzed.
In Vitro Determination of Apoptotic Rates
Apoptotic rates in TMZ-S versus TMZ-LTTHs683 cells were deter-
mined using flow cytometry after annexin V staining. Hs683 cells were
harvested by trypsinization, resuspended in serum-containing medium
to neutralize the trypsin, and washed twice with PBS. Cells were then
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resuspended in ice-cold 1× binding buffer (Sigma-Aldrich, Bornem,
Belgium) at a density of 106 cells/ml and stained with 5 μl of annexin
V–fluorescein isothiocyanate and 10 μl of propidium iodide (PI;
Sigma-Aldrich) as described previously [30]. The fluorescence was
analyzed immediately on a Cell Lab Quanta flow cytometer (Beckman
Coulter Analis, Suarlee, Belgium) equipped with a 488-nm argon laser.
In Vitro Determination of Hs683 Cell Invasive Features
Invasive features of Hs683 cells in vitrowere assessed bymeans of the
Boyden transwell invasion system (BD BioCoat Matrigel invasion
chambers; BD Biosciences Discovery Labware, Bedford, MA) as
detailed elsewhere [31].
Genomic and Proteomic Analyses
Genomic analyses. Total RNAwas extracted from TMZ-S Hs683-S
or TMZ-LTT Hs683-LTT (after 8 weeks of washout), and the quality
and integrity of the extracted RNA were assessed as detailed previously
[31,32]. Full-genome analyses were performed at the VIB Microarray
Facility (UZ Gasthuisberg, Catholic University of Leuven, Leuven,
Belgium) using the Affymetrix Human Genome U133 set Plus 2.0
(High Wycombe, UK). Microarray data analyses were undertaken as
detailed previously [19,20].
Protein expression measurements. Western blot analyses were per-
formed as detailed previously [21,31,33]. Equal loading was verified
by the bright Ponceau red coloration of the membranes, and the integ-
rity and quantity of the extracts were assessed by means of tubulin im-
munoblot analysis. The following primary antibodies were used for
Western blot analysis: anti-Grp78 (dilution 1:1000; Sigma-Aldrich),
anti-GADD34 (dilution 1:500; Santa Cruz Biotechnology, Tebu-bio,
Boechout, Belgium), anti-ATF4 (dilution 1:100; Santa Cruz Biotech-
nology), anti–branched chain amino acid 1 (BCAT1, dilution 1:100;
BD Biosciences, Erembodegem, Belgium), anti-phosphoserine amino-
transferase 1 (PSAT1, dilution 1:1000: Sigma-Aldrich), anti–phospho-p38
mitogen-activated protein kinase (MAPK, dilution 1:250; Cell Sig-
naling Technology, Bioké, Leiden, The Netherlands). Secondary anti-
bodies were purchased from Pierce (PerbioScience, Erembodegem,
Belgium). Western blots were developed using the Pierce Supersignal
Chemiluminescence system.
Reverse Transcription–Polymerase Chain Reaction
The procedure used for the standard reverse transcription–polymerase
chain reaction (RT-PCR) was identical to that described previously
[31,32]. The following primers were used: vimentin forward 5′-gattcag-
gaacagcatgtc-3′ and reverse 5′-tctctagtttcaaccgtctta-3′, CK20 forward
5′-gaacctaaatgaccgtctagc-3′ and reverse 5′-ccaaatctgttttatgtaagggttag-3′,
CD44 forward 5′-ggcttagacagagttgatct-3′ and reverse 5′-ggctatgagacttg-
tatcactac-3′, CD133 forward 5′-gagagtaactaggattctagctt-3′ and reverse
Figure 1. (A) Morphologic illustration (hematoxylin-eosin staining,
×40) of a TMZ-S Hs683 oligodendroglioma xenograft in the brain of
an immunocompromised mouse after having orthotopically injected
105 TMZ-S Hs683 tumor cells 17 days earlier. T indicates tumor; BP,
brain parenchyma. (B) Survival of immunocompromised mice with
brain xenografts of TMZ-S (black circles) versus TMZ-LTT (black
squares) Hs683 oligodendroglioma cells. Mice have been orthoto-
pically grafted into their brains with 105 Hs683 tumor cells on day 0
(D0). Hs683 oligodendroglioma cell populations that have been left
untreated with TMZ are labeled as TMZ-S Hs683 cells, whereas
Hs683 oligodendroglioma cells that have been able to grow in vitro
over months in the presence of 1 mM TMZ have been labeled TMZ-
LTT Hs683 cells (seeMaterials andMethods). (C) Survival of immuno-
compromised mice with brain xenografts of TMZ-S Hs683 cells
treated (open circles) or not (black circles) with TMZ compared to
TMZ-LTT Hs683 cells treated (open squares) or not (black squares)
with TMZ. The TMZ treatment (80 mg/kg per os) was given three
times aweek (Monday,Wednesday, Friday) during three consecutive
weeks, with treatment starting at D5.
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5′-ccattcgacgatagtacttagc-3′, MELK forward 5′-gtgaatccagatcaactgttg-3′
and reverse 5′-gctagataggatgtcttccacta-3′, and actin forward 5′-ctaagtca-
tagtccgcctag-3′ and reverse 5′-aaatcgtgcgtgacattaagg-3′. The PCR condi-
tions for all primer pairs, except actin, were predenaturation (4 minutes
at 94°C), PCR amplification (35 cycles at 94°C for 30 seconds [denatur-
ation], 59°C for 30 seconds [annealing], 72°C for 1 minute [extension]),
and final extension (1 cycle at 72°C for 10 minutes). For actin, the PCR
conditionswere predenaturation (4minutes at 94°C), PCR amplification
(25 cycles at 94°C for 30 seconds [denaturation], 62°C for 30 seconds
[annealing], 72°C for 1 minute [extension]), and final extension (1 cycle
at 72°C for 10 minutes).
Quantitative RT-PCR has been performed in TMZ-S and TMZ-
LTTHs683 oligodendroglioma cells to determine the levels of MGMT
expression. The following primers were used: forward GCGCACCG-
TTTGCGACTTGG and reverse GCACTGCATCAGGGGCTCCG
(35 cycles at 60°C).
Statistical Analyses
Survival analyses were carried out by means of Kaplan-Meier curves
that were compared with the log-rank test. Statistical comparisons be-
tween TMZ-S and TMZ-LTT groups were established by carrying out
the nonparametric Mann-Whitney test. All the statistical analyses were
realized using Statistica (Statsoft, Tulsa, OK).
Results
Chronic In Vivo Treatment of TMZ-S and TMZ-LTT Hs683
Orthotopic Oligodendroglioma Xenografts with TMZ
The Hs683 oligodendroglioma model is biologically aggressive as
illustrated in Figure 1A. Indeed, the orthotopic injection of 105 Hs683
cells only into the brains of immunocompromised mice leads to the
development of highly invasive tumors (T; Figure 1A) everywhere in
the brain parenchyma (BP; Figure 1A).
Hs683 cells that have never been cultured in the presence of
TMZ (TMZ-S Hs683 cells) and Hs683 cells that have been rendered
capable of growth in vitro in the presence of 1 mM TMZ (TMZ-LTT
Hs683 cells) were orthotopically grafted (105 cells per graft) into the
brains of immunocompromised mice. The data in Figure 1B show that
TMZ-LTT Hs683 oligodendroglioma-bearing mice survived signifi-
cantly (P < .05) longer than TMZ-SHs683 oligodendroglioma-bearing
ones. Moreover, whereas TMZ treatment only slightly, nevertheless,
significantly (P < .05), increased the survival of TMZ-S Hs683 oligo-
dendroglioma-bearingmice, itmarkedly (P < .001) increased the survival
of TMZ-LTT Hs683 oligodendroglioma-bearing ones (Figure 1C ).
We observed no morphologic differences between histologically ana-
lyzed TMZ-LTT versus TMZ-S Hs683 tumors (data not shown).
Characterization of Cancer Stem Cell Profiles in TMZ-LTT
versus TMZ-S Hs683 Oligodendroglioma Cells
Beier et al. [34] have recently demonstrated that TMZ induces a
dose- and time-dependent decline of the stem cell subpopulation (i.e.,
CD133+ cells) in various experimental glioma models. We have thus
analyzed the expression of CD133 as well as other stem cells markers
such asCD44, nestin, and thematernal embryonic leucine zipper kinase
(MELK) [35,36] in TMZ-LTT Hs683 cells compared with TMZ-S
cells. The RT-PCR analyses (Figure 2A) revealed that CD44, nestin,
and MELK patterns of expression are similar in Hs683 TMZ-S versus
TMZ-LTT cells. In contrast, long-term TMZ treatment eliminated
CD133+ Hs683 cells (Figure 2A). These data thus perfectly fit in with
those reported by Beier et al. [34]. The human HT-29 colon cancer
Figure 2. (A) mRNA expression (RT-PCR analyses) of vimentin, cytokeratin 20 (CK20), CD133, MELK, and CD44 in Hs683 oligodendroglioma
cell populations that havebeen left untreated (TMZ-SHs683 cells) or that have been able to grow in vitro overmonths in the presenceof 1mM
TMZ (TMZ-LTT Hs683 cells; see Materials and Methods). HT-29 colon cancer cells have been used as an internal control. Actin RT-PCR was
used as a quality control for the reverse transcription and the PCR. (B) Quantitative determination of MGMTmRNA expression (quantitative
RT-PCR) in TMZ-S versus TMZ-LTT Hs683 oligodendroglioma cells. Wild-type U373 and T98G astroglioma cells [11,18,21] have been chosen
as internal references.
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cells were used as a reference cell population illustrating the absence of
vimentin and the presence of cytokeratin CK20 expression in these cells
(Figure 2).
Characterization of MGMT Expression in TMZ-S versus
TMZ-LTT Hs683 Oligodendroglioma Cells
As indicated in the Introduction, it is well known that glioma
cells acquire resistance to TMZ for a longitudinal treatment by over-
expressing MGMT. The data in Figure 2B show that TMZ-LTT
Hs683 cells do not overexpress MGMT, at least at the mRNA levels,
when compared with TMZ-S Hs683 cells.
Genomic and Proteomic Analyses of TMZ-LTT versus TMZ-S
Hs683 Oligodendroglioma Cells
To partly decipher how long-term TMZ in vitro treatment of Hs683
oligodendroglioma cells confers this model with marked increased
TMZ sensitivity in vivo (Figure 1), we made use of a whole human
genome analysis. The expression levels of 1447 genes were found to
be increased or decreased at least two-fold in TMZ-LTT compared with
TMZ-S Hs683 cells. We then subjected this list of 1447 genes to a
functional analysis using the Expression Analysis Systematic Explorer
software package (Ease, version 2.0) [37]. This software gathers biologic
information on the genes and identifies statistically overrepresented
functional categories within a given list of genes. The significantly over-
represented functional categories extracted from this series of 1447
genes were all related to amino acid metabolism (Table 1). Indeed, there
were 36 genes (of 1447) involved in amino acid metabolism whose ex-
pression was impaired in TMZ-LTT Hs683 cells compared to TMZ-S
Hs683 cells (Table 2).
Figure 3 illustrates the data obtained at the protein level with respect
to 2 of the 36 genes listed in Table 2, that is, BCAT1 (cytosolic) and
PSAT1. These two genes are involved in amino acid metabolism and
have been shown to play a role in tumor cell growth [38,39], apoptosis
[40], and chemoresistance [41]. Western blot analyses show that TMZ-
LTTHs683 cells overexpressed BCAT1 and PSAT1 proteins compared
with TMZ-S Hs683 cells (Figure 3). This increased expression of
BCAT1 and PSAT1 proteins was not observed when TMZ-S Hs683
cells were challenged in vitro with a single 100-μMTMZ treatment for
72 hours (Figure 3), a feature that suggests the necessity for prolonged
TMZ challenges of Hs683 cells to observe BCAT1 and PSAT1 expres-
sion increases.
Table 2 reveals that long-term TMZ treatment decreases BCAT1
and PSAT1 expression at the mRNA levels in Hs683 oligodendro-
glioma cells, whereas Figure 3 illustrates an increase of BCAT1 and
PSAT1 expression at the protein levels during long-term TMZ treat-
ment. These apparent contradictory data therefore suggest that, where-
as long-term TMZ treatment decreases the transcriptional activity of
various genes implicated in amino acid metabolism (including BCAT1
and PSAT1), such a decrease in transcriptional activity—that could be
translated as an “alarm signal” by Hs683 cells—activates the translation
of preexisting mRNA into proteins.
The endoplasmic reticulum stress response (ERSR) actively contri-
butes in defending cells in general and cancer cells in particular when
these cells face adverse effects. Further analysis of the list of the 1447
genes whose expressions were modified in TMZ-LTTHs683 cells com-
pared with TMZ-S Hs683 cells revealed that many genes in this list are
indeed involved in the ERSR process, including several genes coding
for chaperones proteins and for components of the PKR-like endo-
plasmic reticulum kinase (PERK) signaling pathway (Table 3). ERSR
activation and especially the PERK signaling pathway (Figure 4A) has
been demonstrated to modulate the expression of genes involved in
amino acid metabolism, including PSAT1 and BCAT1 [41,42]. More-
over, the activation of the PERK signaling pathway by the MAPK p38
kinase was also shown to modulate tumor cell dormancy (Figure 4A)
[43], a feature that could explain the increase of survival of TMZ-
LTT Hs683 oligodendroglioma-bearing mice compared with the
TMZ-S Hs683 oligodendroglioma-bearing ones (Figure 1C). We have
thus analyzed the expression levels of several components and targets of
the PERK signaling pathway, as well as the activation level of p38
MAPK. As illustrated in Figure 4B, the protein expression levels of
Grp78, ATF4, and GADD34 were not modified in TMZ-LTT
Hs683 cells compared to TMZ-S Hs683 cells. In contrast, the phos-
phorylation level of the MAPK p38 kinase was increased in TMZ-LTT
compared with TMZ-S Hs683 cells, suggesting a constitutive activa-
tion of p38 MAPK in TMZ-LTT compared with TMZ-S Hs683 cells
(Figure 4B). A single TMZ in vitro treatment of 100 μM for 72 hours
did not activate p38 MAPK (Figure 4B), a feature that is identical to
what we observed for BCAT1 and PSAT1 protein expression (Figure 3).
Altogether these data thus suggest that long-term TMZ in vitro
treatment of Hs683 cells could push them in a tumor cell dormancy
state through constitutive p38 MAPK activation, without activation
of the PERK signaling pathway. We further investigated this hypoth-
esis as detailed below.
Table 1. Gene Categories Overrepresented in the Set of Genes Detected as Differentially Expressed in TMZ-LTT Compared with TMZ-S Hs683 Cells.
System Gene Category List Population Ease Score Bootstrap Score
Hits Total Hits Total
Biologic process Amine metabolism 36 588 328 10,937 0.00008 0.006
Biologic process Amino acid and derivative metabolism 32 588 290 10,937 0.0002 0.01
Biologic process Amine biosynthesis 14 588 80 10,937 0.0003 0.02
Biologic process Amino acid metabolism 27 588 252 10,937 0.001 0.07
System refers to the system of categorizing genes (e.g., “Biologic process”) in the databases provided by the Ease software package.
Gene Category refers to the specific category of genes within the System (e.g., “Amine metabolism”).
List Hits refers to the number of genes in the list of differentially expressed genes (list_diff resulting from the microarray data analysis) that belong to the Gene Category.
List Total refers to the number of genes in list_diff that belong to any Gene Category within the System.
Population Hits is the number of genes in the total group of genes assayed (list_tot) that belong to the specific Gene Category.
Population Total refers to the number of genes in list_tot that belong to any Gene Category within the System.
The EASE score is the probability value characterizing the change of proportion between the two ratios: population hits/population total and list hits/list total. It constitutes the upper band of the
distribution of leave-one-out Fisher exact probabilities computed on these two ratios.
The Bootstrap method is an iteratively running overrepresentation analysis on random gene lists to determine true probability more accurately.
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In Vitro Characterization of Growth Kinetics (Proliferation
versus Apoptosis) and Invasion Properties of TMZ-LTT versus
TMZ-S Hs683 Oligodendroglioma Cells
Tumor cell dormancy is a phenomenon often related to sustain
ERSR process that arise due to either cell cycle arrest or a dynamic
equilibrium state in which cell proliferation is in balance with cells un-
dergoing death (usually apoptosis). We have thus analyzed the mitotic
and apoptotic rates in TMZ-S and TMZ-LTT Hs683 cells. The data
illustrated in Figure 5 show that TMZ-LTT Hs683 cells display
weaker proliferative activity (Figure 5A) and higher apoptosis (and also
necrosis) levels (Figure 5B) than TMZ-S Hs683 cells. In addition,
Boyden chamber assay revealed that TMZ-LTT Hs683 cells display
Figure 3.Western blot analysis of BCAT1 and PSAT1 expression in Hs683 oligodendroglioma cell populations that have been left untreated
(TMZ-S Hs683 cells) or that have been able to grow in vitro over months in the presence of 1 mM TMZ(TMZ-LTT Hs683 cells; see Materials
and Methods), and in TMZ-S Hs683 cells treated with 100 μM TMZ for 72 hours. Tubulin was used as quality and loading control.
Table 2. Amino Acid Metabolism–Related Gene Whose Expression Is Modified in TMZ LTT Hs683 Cells.
Gene Symbol Gene Name Hs683 TMZ-S Hs683 TMZ-LTT Ratio TMZ-S/TMZ-LTT
Genes downregulated in TMZ-LTT Hs683 cells
HPD 4-Hydroxyphenylpyruvate dioxygenase 258 15 12.9
BCAT1 Branched chain aminotransferase 1, cytosolic 345 25 12.8
CPS1 Carbamoyl-phosphate synthetase 1, mitochondrial 1849 277 5.2
CBS Cystathionine-β-synthase 263 56 4.3
PSAT1 Phosphoserine aminotransferase 1 3735 996 3.7
WARS Tryptophanyl-tRNA synthetase 1074 286 3.5
GFPT1 Glutamine-fructose-6-phosphate transaminase 1 1822 495 3.4
SLC3A1 Solute carrier family 3, member 1 28 8 3.3
PSPH Phosphoserine phosphatase 564 174 3.2
ASNS Asparagine synthetase 4167 1214 3.2
IDS Iduronate 2-sulfatase (Hunter syndrome) 215 65 3.1
CTPS CTP synthase 878 295 3.0
WWOX WW domain containing oxidoreductase 190 66 2.9
GSTZ1 Glutathione transferase zeta 1 (maleylacetoacetate isomerase) 253 92 2.6
MARS Methionine-tRNA synthetase 1988 768 2.6
AARS Alanyl-tRNA synthetase 2875 1014 2.5
HYOU1 Hypoxia-upregulated 1 1624 535 2.5
GAMT Guanidinoacetate N -methyltransferase 111 43 2.5
ARSJ Arylsulfatase family, member J 74 18 2.5
ARG2 Arginase, type II 77 26 2.4
CARS Cysteinyl-tRNA synthetase 537 203 2.3
DIO1 Deiodinase, iodothyronine, type I 22 9 2.2
AGMAT Agmatine ureohydrolase (agmatinase) 258 96 2.1
HSD17B6 Hydroxysteroid (17-β) dehydrogenase 6 32 14 2.1
ABAT 4-Aminobutyrate aminotransferase 48 20 2.1
PHGDH Phosphoglycerate dehydrogenase 785 348 2.1
GARS Glycyl-tRNA synthetase 4951 2247 2.0
DDC Dopa decarboxylase (aromatic L-amino acid decarboxylase) 277 131 2.0
Genes upregulated in TMZ-LTT Hs683 cells
GLCE Glucuronic acid epimerase 247 885 0.30
SULT1C1 Sulfotransferase family, cytosolic, 1C, member 1 10 33 0.30
ARHGAP24 Rho GTPase activating protein 24 76 201 0.4
ASS1 Argininosuccinate synthetase 1642 4745 0.4
HAL Histidine ammonia-lyase 13 70 0.4
KDELC1 KDEL (Lys-Asp-Glu-Leu) containing 1 130 314 0.4
MAOA Monoamine oxidase A 11 33 0.5
SULT1A1 Sulfotransferase family, cytosolic, 1A, member 1 634 1452 0.5
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weaker (P < .01) invasive properties than TMZ-S Hs683 tumor cells
(Figure 5C).
Discussion
TMZ is an alkylating agent that is part of most current therapeutic
regimens for highly malignant gliomas, including not only glioblas-
tomas [3,4,44] but also highly malignant oligodendrogliomas [5–7].
This is the first report on TMZ LTTof human oligodendroglioma cells
with the use of the Hs683 experimental oligodendroglioma as a model.
However, the current study relies on in vitro experiments: in vitro long-
term exposure of glioma cells to TMZ is not an identical condition to
in vivo longitudinal treatment. We thus envisage in future experiments
to analyze gene expression profiles in astroglioma and oligodendro-
glioma xenografts as well as in biopsies from glioma patients who bene-
fited from long-term TMZ treatment.
We observed in the current study thatHs683 oligodendroglioma cells
that have been treated over months in vitro with TMZ (the Hs683 cell
line that we labeled TMZ-LTT Hs683 cells in the present study) are
slightly, nevertheless, significantly less aggressive biologically than
Hs683 cells that have been left untreated (the Hs683 cell line that we
labeled TMZ-S Hs683 cells in the present study), a feature that we ob-
served both in vitro (Figure 5) and in vivo (Figure 1). We found that
treating immunocompromised mice bearing orthotopic xenografts of
TMZ-LTT versus TMZ-S Hs683 cells with the same TMZ regimen
showed markedly higher therapeutic benefits of TMZ in TMZ-LTT
Hs683-bearing mice than in TMZ-S ones (Figure 1).
Gliomas contain both progenitor (stem) cells (cancer stem cells,
CSCs) and differentiated malignant cells [35,36]. Beier et al. [34] have
recently demonstrated that TMZ induces a dose- and time-dependent
decline of the stem cell subpopulation (i.e., CD133+ cells) in various
experimental glioma models. The data illustrated in Figure 2 perfectly
fit inwith those reported byBeier et al. [34]. Indeed, we also observed an
almost complete disappearance of CD133+ CSCs in TMZ-LTTHs683
tumor populations compared with TMZ-S ones. Beier et al. [34] also
claimed that their data strongly suggest that optimized TMZ-based
chemotherapeutic protocols might substantially improve the elimina-
tion of GBM stem cells and, consequently, prolong the survival of
patients, knowing that CSCs may be uniquely responsible for GBM re-
currence [34]. Our data illustrated in Figure 1 fully support conclusions
drawn by Beier et al. [34] about optimized TMZ-based chemotherapy
prolonging the survival of glioma patients. The fact that CD133 expres-
sion disappeared with long-term TMZ treatment, whereas CD44 expres-
sion did not (Figure 2), could appear surprising at first glance because both
markers are usually considered as stem cellmarkers. In fact, CD44 is a glial
progenitor marker [45], whereas CD133 is a marker for a subset of
leukemia and GBMCSCs [46]. CD133GBM-positive cells are resistant
to chemotherapeutic agents, including TMZ [46]. The current data thus
indicate that long-term TMZ treatment eliminated CD133-positive
stem cells in Hs683 oligodendroglioma cell populations (increasing,
therefore, their sensitivity to TMZ), whereas not modifying the glial na-
ture of these cell populations (the maintenance of CD44 positivity).
Apart from diminishing the proportion of CSC versus more differ-
entiated cell subpopulations in gliomas [34] (and our current data),
TMZ could also provide therapeutic benefits during LTT of gliomas
by modifying the levels of expression of various gene products dis-
playing proangiogenic and promigratory influences in glioma cell
populations. For example, we have demonstrated that chronic in vitro ex-
posure to increasing concentrations of TMZ decreases the expression
levels of hypoxia-inducible factor-1α, inhibitor of DNA binding/
differentation proteins 1 and 2, and cMyc in various experimental gliomas
[11]. All these factors have been shown to playmajor roles in angiogenesis
and adaptation to hypoxic metabolism [11].We have performed in the
current study a whole-genome expression analysis comparing TMZ-S
versusTMZ-LTTHs683 cell populations and discovered that the long-
term TMZ treatment of Hs683 oligodendroglioma cells markedly
modified gene patterns of expression of a large set of genes involved
in amino acid metabolism. There is growing evidence that metabolic
enzymes can in fact directly contribute to carcinogenesis [47]. More-
over, it has been shown that amino acid imbalance inhibits the growth
of gastric carcinoma cells in vitro [48]. Our results show that LTT of
Hs683 oligodendroglioma cells with TMZ increases the protein ex-
pression of BCAT1 and PSAT1. PSAT1 is implicated in catabolism:
it catalyzes the second reaction step in the biosynthesis of the amino
acid serine [38]. The overexpression of PSAT1 was shown to stimulate
cell growth and increases chemoresistance of colon cancer cells [38].
BCAT1 is one of the enzymes that regulate the first step in the degradation
Table 3. ER Stress–Related Gene Whose Expression Is Modified in TMZ LTT Hs683 Cells.
Gene Symbol Gene Name Hs683 TMZ-S Hs683 TMZ-LTT Ratio TMZ-S/TMZ-LTT
PERK signaling pathway
HSP5A (Grp78) Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) 14,912 6873 0.46
EIF2AK3 (PERK) Eukaryotic translation initiation factor 2-α kinase 3 937 440 0.47
DDIT3 (CHOP) DNA damage–inducible transcript 3 1613 239 0.15
PPP1R15A (GADD34) Protein phosphatase 1, regulatory (inhibitor) subunit 15A 370 165 0.44
EIF5 Eukaryotic translation initiation factor 5 3332 819 0.24
EIF4BP1 Eukaryotic translation initiation factor 4E binding protein 1 1630 676 0.41
EIF4BP2 Eukaryotic translation initiation factor 4E binding protein 2 72 190 2.58
Chaperones
HYOU1 (ORP150) Hypoxia-upregulated 1 1624 534 0.32
DNAJBA1 DnaJ (Hsp40) homolog, subfamily A, member 1 564 1492 2.64
DNAJB9 (MDG1) DnaJ (Hsp40) homolog, subfamily B, member 9 2019 404 0.20
DNAJB11 DnaJ (Hsp40) homolog, subfamily B, member 11 2690 1224 0.41
DNAJB13 DnaJ (Hsp40) related, subfamily B, member 13 97 38 0.39
DNAJC6 DnaJ (Hsp40) homolog, subfamily C, member 6 257 84 0.32
DNAJC12 DnaJ (Hsp40) homolog, subfamily C, member 12 178 861 4.83
DNAJC15 DnaJ (Hsp40) homolog, subfamily C, member 15 24 81 3.37
HSPA8 Heat shock 70 kDa protein 8 2146 5006 2.33
HSPA1A Heat shock 70 kDa protein 1A 835 3390 4.06
HSPA1B Heat shock 70 kDa protein 1B 208 1070 5.14
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of branched chain amino acids. The overexpression of BCAT1 has
been shown to lead to a decrease in cell viability [40] and the depletion
of BCAT1 was shown to block cell proliferation [48]. We showed that
whereas long-term TMZ treatment decreased BCAT1 and PSAT1
expression at the mRNA levels in Hs683 oligodendroglioma cells
(Table 2), it increased BCAT1 and PSAT1 expression at the protein
levels in these tumor cells (Figure 3). We suggest that it is the TMZ-
induced decrease in BCAT1 and PSAT1 transcriptional activity that
induces an increase in BCAT1 and PSAT1 translational activity by
TMZ-attacked Hs683 tumor cells as a mechanism of defense of
Hs683 tumor cells against TMZ if one refers to the procarcinogenic
effects already described for PSAT1 [39] as well as for its protective
effects in cancer cells facing chemotherapy-related adverse effects [38].
It has also been demonstrated that, at the mRNA level, PSAT1 is a pre-
dictor of tamoxifen therapy response in steroid hormone receptor–
positive patients with recurrent breast cancer [49].
The molecular circuit that activates BCAT1 and PSAT1 translational
activity by TMZwhile their transcriptional activity is partially impaired
by TMZ remains to be identified, but we suspect the ERSR and the
unfolded protein response (UPR) to be both involved in this process.
Indeed, we previously observed that glioma cells are able to defend
themselves against TMZ by overexpressing, for example, galectin-1,
which displays marked proangiogenic [20,26] and promigratory
[50,51] effects in glioma cells. We showed that reducing galectin-1
expression in TMZ-treated glioma cells significantly increases the thera-
peutic benefits contributed by TMZ in the Hs683 oligodendroglioma
model [19]. We observed that these events were related to modifica-
tions occurring at the molecular level of both the ERSR and the UPR
Figure 4. (A) PERK activation by Grp78 under stress condition lead to the phosphorylation of eIF2α, which activates the translation of the
transcription factor ATF4, which in turn regulates gene expression in response to environmental stresses; p38 MAPK activation induces
growth arrest and tumor cell dormancy through the activation of PERK and also through the suppression of ERK signaling. (B) Western
blot analyses of Grp78, Grp94, GADD34, ATF4, and phospho-p38 MAPK expression in TMZ-S versus TMZ-LTT Hs683 cells and in TMZ-S
Hs683 cells treated with 100 μM TMZ for 72 hours (see the legend to Figure 3). Tubulin was used as a quality and loading control.
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processes [19,20]. Harding et al. [42] have shown that the integrated
stress response pathway initiated by the activation of PERK (Figure 4A)
regulates amino acid metabolism and resistance to oxidative stress.
These authors have compared the profile of genes expressed in un-
stressed and in ER-stressed wild type, ATF4−/−, and PERK−/− mouse
embryonic fibroblast. They observed that the ATF4−/− and PERK−/−
cells were severely impaired in activating genes involved in amino acid
import and metabolism [42]. Moreover, Lecca et al. [41] have shown
that UPR induces the coordinated transcriptional activation of genes
encoding proteins involved in the synthesis and the transport of amino
acid. These authors have thus suggested that the amino acid response
might be a component of the UPR [41].
We further demonstrate in the current study that LTT of Hs683
oligodendroglioma cells with TMZ induces constitutive activation of
the stress activated MAP kinase p38 (Figure 4B). The p38 MAPK
activates the PERK signaling pathway, which in turn induces growth
arrest and tumor cell dormancy [43]. The fact that we did not observe
TMZ-induced activation of the PERK signaling pathway at the protein
levels (Figure 4B), whereas we observed TMZ-induced constitutive
activation of p38 MAPK (Figure 4B), suggests that the long-term
TMZ treatment could induce a dormancy state in Hs683 oligodendro-
glioma cells through signaling pathways that would involve ERK and/or
NF-κB [52]. It is postulated that the stress-dependent activation of
p38 may eliminate cells through apoptosis but that the cells that are
able to cope with stress may resume growth or enter a p38-dependent
state of dormancy [43,53,54]. Results in the current study seem to fit
with this hypothesis. Indeed, the LTT of Hs683 cells with TMZ in-
duced a reduction in the percentage of mitotic cells and an increase in
the percentage of apoptotic cells (Figure 5). Moreover, we have also
observed that the TMZ-LTTHs683 cells were significantly less aggres-
sive biologically in vivo than the TMZ-S Hs683 cells (Figure 1), a
feature that could also relate to TMZ-induced dormancy state.
The dormancy state is usually associated with drug resistance [43,54];
however, in our model, the LTTof Hs683 cells with TMZ before their
grafting in the brain of immunocompromised mice seems to render
them more sensitive to TMZ treatment (Figure 1D). Thus, if TMZ ac-
tually induces a dormancy state in Hs683 cells, this dormancy state
seems only partial.
To conclude, we hypothesize that LTTof Hs683 oligodendroglioma
cells with TMZ induces a moderate p38-dependant dormancy state,
resulting in a metabolic change, a growth delay, and a decrease in inva-
sive properties in these long-term TMZ-treated Hs683 tumor cells
with, as a general consequence, a marked increased sensitivity to further
TMZ treatment in these cells when transplanted in vivo.
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